[go: up one dir, main page]

DK2637668T3 - Ibat-inhibitorer til behandling af leversygdomme - Google Patents

Ibat-inhibitorer til behandling af leversygdomme Download PDF

Info

Publication number
DK2637668T3
DK2637668T3 DK11840392.2T DK11840392T DK2637668T3 DK 2637668 T3 DK2637668 T3 DK 2637668T3 DK 11840392 T DK11840392 T DK 11840392T DK 2637668 T3 DK2637668 T3 DK 2637668T3
Authority
DK
Denmark
Prior art keywords
phenyl
carbamoyl
methylthio
formula
dioxo
Prior art date
Application number
DK11840392.2T
Other languages
English (en)
Inventor
Per-Göran Gillberg
Hans Graffner
Ingemar Starke
Original Assignee
Albireo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albireo Ab filed Critical Albireo Ab
Application granted granted Critical
Publication of DK2637668T3 publication Critical patent/DK2637668T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Steroid Compounds (AREA)
  • Control Of Temperature (AREA)

Claims (16)

1. Forbindelse med formlen II
Formel II i hvilken Mer CH2 eller NH; R1 er H eller hydroxy; R2 er H, CH3, -CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, -CH(CH3)CH2CH3, -CH2OH, -CH2OCH3, -CH(OH)CH3j -CH2SCH3 eller -CH2CH2SCH3; eller et farmaceutisk acceptabelt salt deraf, til anvendelse ved forebyggelse og/eller behandling af en leversygdom valgt fra gruppen bestående af Alagilles syndrom (ALGS), progressiv familiær intrahepa-tisk cholestase (PFIC), primær biliær cirrhose (PBC), primær skleroserende cholangitis (PSC) og pruritus ved cholestatisk leversygdom.
2. Forbindelse til anvendelse ifølge krav 1, hvor forbindelsen med formlen II er valgt fra gruppen bestående af: 1.1 -dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-a-[N-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin; 1.1 -dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-a-[N'-((S)-1 -carboxyethyl) carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepin; 1.1 -dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(/V-{(R)-a-[A/-((S)-1 -carboxypropyl) carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin; 1.1 -dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(A/-{(R)-a-[A/-((R)-1 -carboxy-2-methylthioethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin; 1.1 -dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(/V-{(R)-a-[A/-((S)-1 -carboxypropyl) carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin; 1.1 -dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(/V-{(R)-a-[/V-((R)-1 -carboxy-2-methylthio-ethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin; 1.1 -dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(A/-{(R)-a-[A/-((S)-1 -carboxy-2-methylpropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin; 1.1 -dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(/V-(R)-a-[A/-((S)-1 -carboxy-2-(R)-hydroxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin; 1.1 -dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(/V-{(R)-a-[A/-((S)-1 -carboxybutyl) carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin; 1.1 -dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(/V-{(R)-a-[A/-((S)-1 -carboxyethyl) carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin; 1, 1 -dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N-{(R)-a-[N'-((S)-1 -carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepin; 1.1 -dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(/V-{(R)-a-[A/-((S)-1 -carboxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin; 1.1 -dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(/V-{(R)-a-[A/-((S)-1 -carboxy-2-methylpropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin; og 1.1 -dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-1 '-phenyl-1 '-[N'-(carboxymethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepin, eller et farmaceutisk acceptabelt salt deraf.
3. Forbindelse til anvendelse ifølge krav 1 eller 2, hvor forbindelsen med formlen II er 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(A/-{(R)-a-[/V-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin, eller et farmaceutisk acceptabelt salt deraf.
4. Forbindelse til anvendelse ifølge krav 1 eller 2, hvor forbindelsen med formlen II er 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-1'-phenyl-1'-[N'-(carboxymethyl)-carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro- 1,5-benzothiazepin, eller et farmaceutisk acceptabelt salt deraf.
5. Forbindelse ifølge ethvert af kravene 1 til 4, hvor leversygdommen er Alagilles syndrom (ALGS).
6. Forbindelse ifølge ethvert af kravene 1 til 4, hvor leversygdommen er progressiv familiær intrahepatisk cholestase (PFIC).
7. Forbindelse ifølge ethvert af kravene 1 til 4, hvor leversygdommen er primær biliær cirrhose (PBC).
8. Forbindelse ifølge ethvert af kravene 1 til 4, hvor leversygdommen er primær skleroserende cholangitis (PSC).
9. Forbindelse ifølge ethvert af kravene 1 til 4, hvor leversygdommen er pruritus ved cholestatisk leversygdom.
10. Farmaceutisk sammensætning indeholdende en forbindelse med formlen (II)
Formel II i hvilken Mer CH2 eller NH; R1 er H eller hydroxy; R2 er H, CH3, -CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, -CH(CH3)CH2CH3j -CH2OH, -CH2OCH3j -CH(OH)CH3j -CH2SCH3 eller -CH2CH2SCH3; eller et farmaceutisk acceptabelt salt deraf, til anvendelse ved forebyggelse og/eller behandling af en leversygdom valgt fra gruppen bestående af Alagilles syndrom (ALGS), progressiv familiær intrahepa-tisk cholestase (PFIC), primær biliær cirrhose (PBC), primær skleroserende cholangitis (PSC) og pruritus ved cholestatisk leversygdom.
11. Farmaceutisk sammensætning til anvendelse ifølge krav 10, hvori forbindelsen med formlen II er 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(Λ/-{(R)-C(-[Λ/-((S)-1-carboxypropyl)carbamoyl]-4- hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin eller et farmaceutisk acceptabelt salt deraf.
12. Farmaceutisk sammensætning til anvendelse ifølge krav 10, hvori forbindelsen med formlen II er 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-1'-phenyl-1'-[N'-(carboxymethyl)carbamoyl]methyl}carbamoylmethoxy)- 2,3,4,5-tetrahydro-1,5-benzothiazepin eller et farmaceutisk acceptabelt salt deraf.
13. Farmaceutisk kombination til samtidig eller sekventiel indgivelse, der indeholder en forbindelse med formlen II
Formel II i hvilken Mer CH2 eller NH; R1 er H eller hydroxy; R2 er H, CH3, -CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, -CH(CH3)CH2CH3j -CH2OH, -CH2OCH3j -CH(OH)CH3j -CH2SCH3 eller -CH2CH2SCH3; eller et farmaceutisk acceptabelt salt deraf, og ursodeoxycholsyre, til anvendelse ved forebyggelse og/eller behandling af en leversygdom valgt fra gruppen bestående af Alagilles syndrom (ALGS), progressiv familiær intrahepatisk cholestase (PFIC), primær biliær cirrhose (PBC), primær skleroserende cholangitis (PSC) og pruritus ved cholestatisk leversygdom.
14. Farmaceutisk kombination til samtidig eller sekventiel indgivelse, der indeholder en forbindelse med formlen II
Formel II i hvilken Mer CH2 eller NH; R1 er H eller hydroxy; R2 er H, CH3, -CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, -CH(CH3)CH2CH3, -CH2OH, -CH2OCH3, -CH(OH)CH3, -CH2SCH3 eller -CH2CH2SCH3; eller et farmaceutisk acceptabelt salt deraf, og nor-ursodeoxycholsyre, til anvendelse ved forebyggelse og/eller behandling af en leversygdom valgt fra gruppen bestående af Alagilles syndrom (ALGS), progressiv familiær intrahepatisk cholestase (PFIC), primær biliær cirrhose (PBC), primær skleroserende cholangitis (PSC) og pruritus ved cholestatisk leversygdom.
15. Farmaceutisk kombination til anvendelse ifølge krav 13 eller 14, hvori forbindelsen med formlen II er 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(Λ/-{(R)-C(-[Λ/-((S)-1-carboxypropyl)carbamoyl]-4- hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin eller et farmaceutisk acceptabelt salt deraf.
16. Farmaceutisk kombination til anvendelse ifølge krav 13 eller 14, hvori forbindelsen med formlen II er 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-1'-phenyl-1'-[N'-(carboxymethyl)carbamoyl]methyl}carbamoylmethoxy)- 2,3,4,5-tetrahydro-1,5-benzothiazepin eller et farmaceutisk acceptabelt salt deraf.
DK11840392.2T 2010-11-04 2011-11-08 Ibat-inhibitorer til behandling af leversygdomme DK2637668T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1051165 2010-11-04
US41095710P 2010-11-08 2010-11-08
PCT/SE2011/051335 WO2012064266A1 (en) 2010-11-04 2011-11-08 Ibat inhibitors for the treatment of liver diseases

Publications (1)

Publication Number Publication Date
DK2637668T3 true DK2637668T3 (da) 2016-08-29

Family

ID=46051197

Family Applications (3)

Application Number Title Priority Date Filing Date
DK15193953.5T DK3023102T3 (da) 2010-11-04 2011-11-08 Ibat-inhibitorer til behandlingen af leversygdomme
DK18179884.4T DK3400944T3 (da) 2010-11-04 2011-11-08 Ibat-inhibitorer til behandling af leversygdomme
DK11840392.2T DK2637668T3 (da) 2010-11-04 2011-11-08 Ibat-inhibitorer til behandling af leversygdomme

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK15193953.5T DK3023102T3 (da) 2010-11-04 2011-11-08 Ibat-inhibitorer til behandlingen af leversygdomme
DK18179884.4T DK3400944T3 (da) 2010-11-04 2011-11-08 Ibat-inhibitorer til behandling af leversygdomme

Country Status (31)

Country Link
US (15) US20130225511A1 (da)
EP (4) EP3023102B1 (da)
JP (1) JP5889321B2 (da)
KR (1) KR101890959B1 (da)
CN (2) CN103260625B (da)
AU (1) AU2011326871B2 (da)
BR (1) BR112013010157B1 (da)
CA (1) CA2815749C (da)
CY (4) CY1118125T1 (da)
DK (3) DK3023102T3 (da)
ES (2) ES2586931T3 (da)
FR (1) FR22C1002I2 (da)
HR (2) HRP20160993T1 (da)
HU (3) HUE030062T2 (da)
IL (1) IL225601A (da)
LT (4) LT3023102T (da)
LU (1) LUC00242I2 (da)
ME (1) ME02554B (da)
MX (3) MX366925B (da)
MY (1) MY163275A (da)
NL (1) NL301157I2 (da)
NO (1) NO2021054I1 (da)
PL (3) PL2637668T3 (da)
PT (3) PT2637668T (da)
RS (3) RS57778B1 (da)
SG (1) SG190029A1 (da)
SI (3) SI3400944T1 (da)
SM (3) SMT201800453T1 (da)
TR (1) TR201810984T4 (da)
WO (1) WO2012064266A1 (da)
ZA (1) ZA201303057B (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102316872B (zh) 2008-11-26 2016-12-21 萨蒂奥根制药公司 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
KR101890959B1 (ko) 2010-11-04 2018-08-22 알비레오 에이비 간질환 치료를 위한 ｉｂａｔ 억제제
CN103228270B (zh) * 2010-11-08 2016-02-10 阿尔比里奥公司 含ibat抑制剂和胆汁酸结合剂的药物组合
EA030839B1 (ru) * 2011-10-28 2018-10-31 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
WO2013063526A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
JO3301B1 (ar) * 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CA2938406A1 (en) * 2014-01-31 2015-08-06 Janssen Pharmaceutica Nv Methods for the treatment and prevention of renal disorders and fatty liver disorders
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
CN106573033A (zh) * 2014-06-25 2017-04-19 Ea制药株式会社 固体制剂及其稳定化方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
CN105395532B (zh) * 2015-11-25 2017-11-14 中国医学科学院医药生物技术研究所 2‑苯磺酰胺基苯甲酰胺类化合物在肝损伤保护和肝纤维化防治中的应用
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
KR101844184B1 (ko) * 2017-07-21 2018-04-02 씨제이헬스케어 주식회사 아미노알킬벤조티아제핀 유도체의 용도
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
US10428109B1 (en) 2018-03-09 2019-10-01 Elobix Ab Process for the preparation of 1,5-benzothiazepine compounds
BR112020017353A2 (pt) 2018-03-09 2020-12-15 Elobix Ab Processos para a preparação de um composto e de uma modificação de cristal iv de elobixibat.
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US11801226B2 (en) * 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
SG11202012151XA (en) 2018-06-20 2021-01-28 Albireo Ab Crystal modifications of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
MX2021008981A (es) 2019-02-06 2021-09-08 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del acido biliar.
AU2020221834B2 (en) * 2019-02-12 2025-10-23 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency
JP7689076B2 (ja) 2019-09-09 2025-06-05 Ｅａファーマ株式会社 １，５－ベンゾチアゼピン化合物を製造するための方法
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
EP4069360B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
CN114761080B (zh) 2019-12-04 2024-07-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
JP7696898B2 (ja) 2019-12-04 2025-06-23 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
ES3002777T3 (en) 2020-08-03 2025-03-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4243831A1 (en) 2020-11-12 2023-09-20 Albireo AB Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
US20220152012A1 (en) * 2020-11-16 2022-05-19 The Regents Of The University Of California Methods for regressing or reversing fibrosis and/or liver cirrhosis in a subject in need thereof using high-dose niacin, or a niacin analog thereof
EP4255565A1 (en) 2020-12-04 2023-10-11 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
WO2022166680A1 (zh) * 2021-06-25 2022-08-11 苏州科睿思制药有限公司 奥德昔巴特的晶型及其制备方法和用途
TW202333724A (zh) * 2021-11-05 2023-09-01 美商米魯姆製藥公司 以迴腸膽酸轉運蛋白(ibat)抑制劑治療以增加無事件存活期(efs)
WO2023174937A1 (en) 2022-03-16 2023-09-21 Sandoz Ag Particles comprising non-crystalline odevixibat
CN119053330A (zh) 2022-04-22 2024-11-29 阿尔比里奥公司 皮下给药asbt抑制剂
WO2024251739A1 (en) * 2023-06-06 2024-12-12 Glaxosmithkline Intellectual Property (No.2) Limited Novel use of an ileal bile acid transporter inhibitor for the treatment of pruritus
WO2025019330A1 (en) 2023-07-14 2025-01-23 Pleiogenix Inc. Methods of treating fibrotic liver diseases or conditions with indeglitazar

Family Cites Families (242)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE580490A (fr) 1958-07-15 1960-01-08 Merck & Co Inc Compositions et procédés pour abaisser la teneur en cholestérol du sang
US3308020A (en) 1961-09-22 1967-03-07 Merck & Co Inc Compositions and method for binding bile acids in vivo including hypocholesteremics
US3383281A (en) 1961-09-22 1968-05-14 Merck & Co Inc Method for binding bile acids in vivo
FR208F (da) 1964-07-31
US3539380A (en) 1968-01-08 1970-11-10 Upjohn Co Methylcellulose and polyalkylene glycol coating of solid medicinal dosage forms
NL7017227A (da) 1969-12-27 1971-06-29
GB1348642A (en) 1970-10-15 1974-03-20 Howard A N Hypocholesterolaemic compositions
US3769399A (en) 1971-03-05 1973-10-30 L Hagerman Intestinal bile acid binding process and compositions
US3974272A (en) 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4252790A (en) 1974-10-23 1981-02-24 Interx Research Corporation Method for treating gastric ulcer-prone patients
GB1530201A (en) 1976-04-14 1978-10-25 Pfizer Ltd Process for the preparation of aminoglycoside antibiotics and intermediates therefor
GB1566609A (en) 1977-03-10 1980-05-08 Reckitt & Colmann Prod Ltd Pharmaceutical compositions containing cholestyramine and alginic acid
GB1573487A (en) 1977-05-23 1980-08-28 Bristol Myers Co Bile acid binding composition
IT1106718B (it) 1978-12-21 1985-11-18 Alfa Farmaceutici Spa Composizioni a base di resine anioniche salificate farmacologicamente attive
DE3061586D1 (en) 1979-04-30 1983-02-17 Max Planck Gesellschaft Pancreozymin-cholezystokinin active peptides, process for their preparation and pharmaceutical compositions containing them
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB2184122B (en) 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
US4895723A (en) 1986-09-08 1990-01-23 Amer And Company Cholestyramine compositions and method for preparation thereof
US4814354A (en) 1986-09-26 1989-03-21 Warner-Lambert Company Lipid regulating agents
US5167965A (en) 1987-02-09 1992-12-01 The Dow Chemical Company Palatable cholestyramine granules, tablets and methods for preparation thereof
CA1313135C (en) 1987-02-09 1993-01-26 The Dow Chemical Company Cholestyramine composition and process for its preparation
US5049394A (en) 1987-09-11 1991-09-17 E. R. Squibb & Sons, Inc. Pharmaceutical composition containing high drug load and method for preparing same
US4900757A (en) 1988-12-08 1990-02-13 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
US4874744A (en) 1989-03-13 1989-10-17 University Of Cincinnati Method of using melanocyte stimulating hormone as dermatis treatment
JP2800242B2 (ja) 1989-03-30 1998-09-21 大正製薬株式会社 粒剤の製造方法
DE3930168A1 (de) 1989-09-09 1991-03-14 Knoll Ag Verbesserte verabreichungsform fuer colestyramin
IL95574A (en) 1989-09-09 1994-11-11 Knoll Ag Colestyramine preparation
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
JP2542122B2 (ja) 1990-04-18 1996-10-09 旭化成工業株式会社 球状核、球形顆粒およびその製造方法
NZ240846A (en) 1990-12-06 1994-04-27 Hoechst Ag Dimeric bile acid derivatives; preparatory processes and pharmaceutical compositions
NZ245503A (en) 1991-12-20 1995-11-27 Hoechst Ag Polymers containing bile acids; pharmaceuticals and preparatory methods
JPH05186357A (ja) 1991-12-31 1993-07-27 Shigeo Ochi 飲食物消化分解産物吸収抑制手段
GB9203347D0 (en) 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
IT1257793B (it) 1992-05-18 1996-02-13 Composizione farmaceutica a base di acidi biliari in microgranuli a rilascio controllato
CA2137265C (en) 1992-06-04 2003-10-28 Sanjay Bhardwaj Palatable pharmaceutical compositions
DK0573848T3 (da) 1992-06-12 1998-08-10 Hoechst Ag Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler
US5350584A (en) 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
PT621032E (pt) 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
DE4314583A1 (de) 1993-04-29 1994-11-03 Astra Chem Gmbh Colestyramin enthaltende Zusammensetzung und Verfahren zu deren Herstellung
TW289757B (da) 1993-05-08 1996-11-01 Hoechst Ag
TW289021B (da) 1993-05-08 1996-10-21 Hoechst Ag
TW289020B (da) 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
EP0624593A3 (de) 1993-05-08 1995-06-07 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
EP0781278B1 (en) 1994-09-13 2001-03-14 Monsanto Company Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5994391A (en) 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
GB9423172D0 (en) 1994-11-17 1995-01-04 Wellcom Foundation The Limited Hypolipidemic benzothiazepines
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
DE69733132D1 (de) 1996-01-16 2005-06-02 Ronald J Sokol Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
DE19608592A1 (de) 1996-03-06 1997-09-11 Hoechst Ag Antikörper zur selektiven immunologischen Bestimmung von Gallensäuren in biologischen Matrices
EP0888333B1 (en) 1996-03-11 2005-08-31 G.D. Searle LLC Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
CA2253593C (en) 1996-05-23 2008-07-08 Novartis Ag Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-fudca)
WO1998003818A1 (de) 1996-07-24 1998-01-29 Zumtobel Staff Gmbh Adapter für ein haltemittel, welches zum befestigen einer einbauleuchte in einer einbauöffnung bestimmt ist, oder haltemittel oder einbauleuchte mit einem solchen adapter
DE19633268A1 (de) 1996-08-19 1998-02-26 Hoechst Ag Polymere Gallensäure-Resorptionsinhibitoren mit gleichzeitiger Gallensäure-Adsorberwirkung
GB9704208D0 (en) 1997-02-28 1997-04-16 Glaxo Group Ltd Chemical compounds
JP2002500628A (ja) 1997-03-11 2002-01-08 ジー．ディー．サール アンド カンパニー 回腸胆汁酸輸送阻害ベンゾチエピンおよびＨＭＧ Ｃｏ−Ａレダクターゼ阻害剤を用いた併用療法
PT864582E (pt) 1997-03-14 2003-10-31 Aventis Pharma Gmbh 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos
EP0998271B3 (en) 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
WO1998056757A1 (fr) 1997-06-11 1998-12-17 Sankyo Company, Limited Derives de benzylamine
SE9702305D0 (sv) 1997-06-17 1997-06-17 Astra Ab New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
AUPO763197A0 (en) 1997-06-30 1997-07-24 Sigma Pharmaceuticals Pty Ltd Health supplement
US6066336A (en) 1997-09-29 2000-05-23 Bristol-Myers Squibb Company Cholesterol-lowering tablets
US5900233A (en) 1997-10-16 1999-05-04 Day; Charles E. Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
ES2195428T3 (es) 1997-12-19 2003-12-01 Searle & Co Metodo para preparar oxidos de tetrahidrobenzotiepina enriquecidos enantiometricamente.
GB9800428D0 (en) 1998-01-10 1998-03-04 Glaxo Group Ltd Chemical compounds
JP2002513013A (ja) 1998-04-24 2002-05-08 藤沢薬品工業株式会社 グアニジン誘導体
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801990D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19825804C2 (de) 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
EP1103552A4 (en) 1998-08-07 2003-01-15 Takeda Chemical Industries Ltd BENZOTHIEPINE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE
US20030153607A1 (en) 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
HK1045114A1 (zh) 1998-12-23 2002-11-15 G‧D‧瑟尔有限公司 适用於心血管疾病的回肠胆汁酸转运抑制剂和贝酸衍生物的组合
BR9916484A (pt) 1998-12-23 2002-01-22 Searle Llc Combinações de inibidores do transporte de ácido biliar ileal e de agentes sequestrantes de ácido biliar em indicações cardiovasculares
HUP0104593A3 (en) 1998-12-23 2004-10-28 G D Searle Llc Chicago Combinations of benzothiepine ileal bile acid transport inhibitor and nicotinic acid derivatives for cardiovascular indications
PT1140188E (pt) 1998-12-23 2003-10-31 Searle Llc Combinacoes de inibidores do transporte de acidos biliares do ileo e de inibidores da proteina de transferencia de esteres de colesterilo para doencas cardiovasculares.
DE69911058T2 (de) 1998-12-23 2004-06-03 G.D. Searle Llc, Chicago Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
AU3694600A (en) 1999-02-12 2000-08-29 G.D. Searle Llc Novel 1,2-benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DE19915420A1 (de) 1999-04-06 2000-10-12 Basf Ag Stabilisierte Polyvinylpyrrolidon-Zubereitungen
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
SE9901387D0 (sv) 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
US6287609B1 (en) 1999-06-09 2001-09-11 Wisconsin Alumni Research Foundation Unfermented gel fraction from psyllium seed husks
GB9919411D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
GB9919413D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
US20020054903A1 (en) 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
AU1302301A (en) 1999-11-08 2001-06-06 Sankyo Company Limited Nitrogenous heterocycle derivatives
GB9927088D0 (en) 1999-11-17 2000-01-12 Secr Defence Use of poly(diallylamine) polymers
TW574193B (en) 1999-12-03 2004-02-01 Astrazeneca Ab Novel phenalkyloxy-phenyl derivatives, pharmaceutical composition containing the same and their uses
EP1259494A4 (en) 2000-02-18 2004-09-15 Merck & Co Inc ARYLOXYACETIC ACIDS FOR DIABETES AND LIPID DISORDERS
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
AU2001240115A1 (en) 2000-03-10 2001-09-24 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
WO2001068096A2 (en) 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
TWI241195B (en) 2000-04-10 2005-10-11 Shionogi & Co Preventive agent for bile acidic diarrhea
US6638498B2 (en) 2000-06-30 2003-10-28 Semorex Inc. Molecularly imprinted polymers for the treatment and diagnosis of medical conditions
US20020183307A1 (en) 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
RU2241462C2 (ru) 2000-07-28 2004-12-10 Ф. Хоффманн-Ля Рош Аг Новая фармацевтическая композиция
FR2812886B1 (fr) 2000-08-08 2002-11-08 Assist Publ Hopitaux De Paris Depistage d'un nouveau syndrome hepatique et ses applications
SE0003766D0 (sv) 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) * 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
WO2002053548A1 (fr) 2000-12-27 2002-07-11 Banyu Pharmaceutical Co.,Ltd. Derives de la benzothiazepine
US6506921B1 (en) 2001-06-29 2003-01-14 Virginia Tech Intellectual Properties, Inc. Amine compounds and curable compositions derived therefrom
DE10131715B4 (de) * 2001-06-29 2010-03-18 Sms Siemag Aktiengesellschaft Vorrichtung zum Stranggießen von flüssigen Metallen, insbesondere von Stahl, mit auf einem Schwingrahmen angeordneter Stranggießkokille
US20040077625A1 (en) 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
US20040038862A1 (en) 2001-07-30 2004-02-26 Goodwin Bryan James Identification of new therapeutic targets for modulating bile acid synthesis
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
WO2003022286A1 (en) * 2001-09-08 2003-03-20 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
WO2003022804A2 (en) 2001-09-12 2003-03-20 G.D. Searle Llc Method for the preparation of crystalline tetrahydrobenzothiepines
CA2464685A1 (en) 2001-11-02 2003-05-15 G.D. Searle Llc Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
TW200300349A (en) 2001-11-19 2003-06-01 Sankyo Co A 4-oxoqinoline derivative
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
WO2003059378A2 (en) 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
GB0201850D0 (en) * 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
US20040014806A1 (en) 2002-03-08 2004-01-22 Pharmacia Corporation Methods and compositions for lowering levels of blood lipids
US20050089572A1 (en) 2002-03-22 2005-04-28 Manoj Kumar Controlled release drug delivery system of pravastatin
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) * 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0216321D0 (en) * 2002-07-13 2002-08-21 Astrazeneca Ab Therapeutic treatment
US7312208B2 (en) 2002-08-28 2007-12-25 Asahi Kasei Pharma Corporation Quaternary ammonium compounds
CN100494185C (zh) 2002-08-28 2009-06-03 旭化成制药株式会社 新型季铵化合物
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
US7939061B2 (en) 2003-02-28 2011-05-10 Micropharma Limited Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides
WO2004108067A2 (en) 2003-04-03 2004-12-16 Sun Pharmaceutical Industries Limited Programmed drug delivery system
GB0307918D0 (en) * 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
JP5448297B2 (ja) 2003-10-16 2014-03-19 テクコム・グループ・リミテッド・ライアビリティ・カンパニー 低減した血中応答を有する低減可消化炭水化物食物
ATE555101T1 (de) 2004-02-27 2012-05-15 Asahi Kasei Pharma Corp Neue benzothiazepin- und benzothiepinverbindungen
WO2005082414A2 (en) 2004-03-02 2005-09-09 Astellas Pharma Inc. Concomitant drugs of a sulfonamide and another therapeutic agent
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
US20050215882A1 (en) 2004-03-23 2005-09-29 The Regents Of The University Of Michigan Noninvasive method to determine fat content of tissues using MRI
TWI415635B (zh) 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
US20050287178A1 (en) * 2004-06-23 2005-12-29 Steed Barrie L Diagnosis and treatment of heavy gallbladder densities
JP4896480B2 (ja) 2004-10-01 2012-03-14 第一三共ヘルスケア株式会社 陰イオン交換樹脂の粒子状組成物
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
WO2006121861A2 (en) * 2005-05-05 2006-11-16 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
US20080193543A1 (en) 2005-05-17 2008-08-14 Brown University Research Foundation Drug Delivery Formulations For Targeted Delivery
US20070237818A1 (en) 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
DE102005033099A1 (de) 2005-07-15 2007-01-18 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung
DE102005033100B3 (de) 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
KR101368525B1 (ko) 2005-09-20 2014-03-06 노파르티스 아게 저혈당 증상을 저하시키기 위한 ｄｐｐ-ⅳ 억제제의 용도
US8366650B2 (en) 2005-10-24 2013-02-05 Satiogen Pharmaceuticals, Inc. Biliary/pancreatic shunt device and method for treatment of metabolic and other diseases
EP2007395A1 (en) 2006-04-10 2008-12-31 Merck & Co., Inc. Cgrp antagonist salt
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
DE102006053636B4 (de) 2006-11-14 2008-09-18 Sanofi-Aventis Deutschland Gmbh Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung
JP2010509252A (ja) 2006-11-14 2010-03-25 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 改善された特性を有する新規な１，４−ベンゾチエピン−１，１−ジオキシド誘導体、それらの製造方法、上記化合物を含有する薬物、及びそれらの使用
DE102006053637B4 (de) * 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE102006053635B4 (de) 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
RU2314104C1 (ru) 2006-11-23 2008-01-10 Государственное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Федерального агентства по здравоохранению и социальному развитию Способ лечения больных аллергическим ринитом
US20090035306A1 (en) 2006-11-29 2009-02-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
CA2928178C (en) 2007-01-19 2019-09-10 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
WO2008097976A1 (en) 2007-02-09 2008-08-14 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
ES2350029T3 (es) 2007-03-02 2011-01-17 Farnam Companies, Inc. Pellets de liberación sostenida que comprenden un material tipo cera.
PL2200588T3 (pl) 2007-09-25 2019-09-30 Solubest Ltd. Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania
US9295677B2 (en) 2008-02-26 2016-03-29 Qing Bile Therapeutics Inc. Polyhydroxylated bile acids for treatment of biliary disorders
KR20110059750A (ko) 2008-09-02 2011-06-03 유에스브이 리미티드 가교 폴리머
CN102316872B (zh) 2008-11-26 2016-12-21 萨蒂奥根制药公司 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
FR2943342B1 (fr) 2009-03-20 2011-03-04 Servier Lab Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US20110152204A1 (en) 2009-12-18 2011-06-23 Satiogen Pharmaceuticals, Inc. Treatment of Obesity or Diabetes with Bile Acid Sequestrants
HRP20160834T1 (hr) 2010-02-23 2016-09-23 Da Volterra Formulacije za oralnu dopremu adsorbensa u crijevo
JO3131B1 (ar) 2010-04-27 2017-09-20 Glaxosmithkline Llc مركبات كيميائية
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
KR101890959B1 (ko) 2010-11-04 2018-08-22 알비레오 에이비 간질환 치료를 위한 ｉｂａｔ 억제제
MY176863A (en) 2010-11-08 2020-08-24 Albireo Ab Ibat inhibitors for treatment of metabolic disorders and related conditions
US20120114588A1 (en) 2010-11-08 2012-05-10 Albireo Ab Ibat inhibitors for treatment of metabolic disorders and related conditions
CN103228270B (zh) 2010-11-08 2016-02-10 阿尔比里奥公司 含ibat抑制剂和胆汁酸结合剂的药物组合
WO2013063526A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
EA030839B1 (ru) 2011-10-28 2018-10-31 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
PT2848254T (pt) 2012-05-07 2016-10-05 Kissei Pharmaceutical Derivado de pirazol e utilização do mesmo para propósitos médicos
JP2016514684A (ja) 2013-03-15 2016-05-23 ルメナ ファーマシューティカルズ エルエルシー 原発性硬化性胆管炎および炎症性腸疾患の処置のための胆汁酸再循環阻害剤
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
JP2016521279A (ja) 2013-04-30 2016-07-21 アッヴィ・インコーポレイテッド アトラセンタンを使用して脂質プロファイルを改善するための方法
MX2016011063A (es) 2014-02-27 2016-11-30 Nusirt Sciences Inc Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica.
US20170143743A1 (en) 2014-06-16 2017-05-25 Valpharma International S.P.A. Formulation for oral administration containing mesalazine
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
CN106573033A (zh) 2014-06-25 2017-04-19 Ea制药株式会社 固体制剂及其稳定化方法
KR101674806B1 (ko) 2014-10-20 2016-11-10 씨제이헬스케어 주식회사 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US9684018B2 (en) 2014-11-19 2017-06-20 Texas Instruments Incorporated Current sense circuit that operates over a wide range of currents
KR20160061492A (ko) 2014-11-21 2016-06-01 삼성디스플레이 주식회사 휴대용 먼지 센서 및 이를 이용한 휴대전화
CN105985254B (zh) 2015-02-17 2018-03-16 上海中科绿碳化工科技有限公司 一种制备甲酰胺类化合物的方法
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
CA3011595C (en) 2016-02-09 2024-01-02 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CA3011565C (en) 2016-02-09 2024-01-02 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
WO2017138878A1 (en) 2016-02-09 2017-08-17 Albireo Ab Oral cholestyramine formulation and use thereof
US11350844B2 (en) 2016-11-23 2022-06-07 Mayo Foundation For Medical Education And Research System and method for generating nonalcoholic fatty liver disease activity score (NAS) using magnetic resonance elastography
KR101844184B1 (ko) 2017-07-21 2018-04-02 씨제이헬스케어 주식회사 아미노알킬벤조티아제핀 유도체의 용도
JP7328207B2 (ja) 2017-08-09 2023-08-16 アルビレオ・アクチボラグ コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
US10428109B1 (en) 2018-03-09 2019-10-01 Elobix Ab Process for the preparation of 1,5-benzothiazepine compounds
BR112020017353A2 (pt) 2018-03-09 2020-12-15 Elobix Ab Processos para a preparação de um composto e de uma modificação de cristal iv de elobixibat.
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
SG11202012151XA (en) 2018-06-20 2021-01-28 Albireo Ab Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US20200046757A1 (en) 2018-08-09 2020-02-13 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations, and uses thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US20200046758A1 (en) 2018-08-09 2020-02-13 Albireo Ab Oral cholestyramine formulation and use thereof
MX2021003652A (es) 2018-09-27 2021-08-19 Albireo Energy Llc Sistema, aparato y dispositivo vav hibrido con multiples bobinas de calefaccion.
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
MX2021008981A (es) 2019-02-06 2021-09-08 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del acido biliar.
CA3127408A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
AU2020221834B2 (en) 2019-02-12 2025-10-23 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency
US20220105218A1 (en) 2019-02-15 2022-04-07 The Board Of Trustees Of The Leland Standford Junior University Methods and systems for reducing a pathogen population
JP7256540B2 (ja) 2019-03-26 2023-04-12 国立大学法人東北大学 血中尿毒症物質の低減剤
WO2021110883A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN114761080B (zh) 2019-12-04 2024-07-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
AR120676A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
AR120683A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
AR120674A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiazepina y su uso como ácido biliar
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
EP4069360B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110885A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
JP7696898B2 (ja) 2019-12-04 2025-06-23 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
ES3002777T3 (en) 2020-08-03 2025-03-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022101379A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
EP4243831A1 (en) 2020-11-12 2023-09-20 Albireo AB Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
EP4255565A1 (en) 2020-12-04 2023-10-11 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
CN119053330A (zh) 2022-04-22 2024-11-29 阿尔比里奥公司 皮下给药asbt抑制剂
EP4536232A1 (en) 2022-06-09 2025-04-16 Albireo AB Treating hepatitis
AU2023304672A1 (en) 2022-07-05 2025-01-02 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Also Published As

Publication number Publication date
NL301157I2 (nl) 2023-11-09
CN105288580A (zh) 2016-02-03
HUS2100055I1 (hu) 2022-01-28
EP2637668B1 (en) 2016-05-11
US20180162904A1 (en) 2018-06-14
US10000528B2 (en) 2018-06-19
FR22C1002I1 (fr) 2022-02-25
HRP20160993T1 (hr) 2016-12-30
CY2021031I2 (el) 2022-03-24
HUE039506T2 (hu) 2019-01-28
CA2815749C (en) 2019-12-03
US20160193277A1 (en) 2016-07-07
CA2815749A1 (en) 2012-05-18
ES2687027T3 (es) 2018-10-23
US10221212B2 (en) 2019-03-05
IL225601A0 (en) 2013-06-27
SMT202000486T1 (it) 2020-11-10
BR112013010157B1 (pt) 2020-02-04
ES2586931T3 (es) 2016-10-19
EP3400944A1 (en) 2018-11-14
SMT201600331B (it) 2016-11-10
MX338535B (es) 2016-04-21
HK1223566A1 (en) 2017-08-04
US20180030088A1 (en) 2018-02-01
US20180030089A1 (en) 2018-02-01
US12187812B2 (en) 2025-01-07
PT2637668T (pt) 2016-08-17
US9694018B1 (en) 2017-07-04
RS60901B1 (sr) 2020-11-30
NO2021054I1 (no) 2021-12-22
RU2013126116A (ru) 2014-12-20
RS57778B1 (sr) 2018-12-31
ZA201303057B (en) 2015-11-25
HUE030062T2 (en) 2017-04-28
PL2637668T3 (pl) 2017-01-31
AU2011326871A1 (en) 2013-04-11
PL3400944T3 (pl) 2020-11-16
LTPA2021012I1 (da) 2021-11-25
TR201810984T4 (tr) 2018-09-21
LT2637668T (lt) 2016-09-12
HRP20181185T1 (hr) 2018-10-19
ME02554B (me) 2017-02-20
WO2012064266A1 (en) 2012-05-18
CY1123470T1 (el) 2022-03-24
EP2637668A4 (en) 2014-03-26
IL225601A (en) 2017-02-28
US20230109432A1 (en) 2023-04-06
KR20140032952A (ko) 2014-03-17
MX2013005093A (es) 2013-10-17
SMT201800453T1 (it) 2018-11-09
US20200140484A1 (en) 2020-05-07
EP2637668A1 (en) 2013-09-18
US20210340175A1 (en) 2021-11-04
CN103260625A (zh) 2013-08-21
US10093697B2 (en) 2018-10-09
FR22C1002I2 (fr) 2024-03-08
MY163275A (en) 2017-08-30
US20160194353A1 (en) 2016-07-07
US20250257097A1 (en) 2025-08-14
JP2013541584A (ja) 2013-11-14
PT3400944T (pt) 2020-09-30
EP3023102B1 (en) 2018-06-27
DK3023102T3 (da) 2018-09-24
RS55266B1 (sr) 2017-02-28
BR112013010157A2 (pt) 2016-09-13
US20150031636A1 (en) 2015-01-29
CN103260625B (zh) 2016-01-06
LT3400944T (lt) 2020-09-25
US20180362577A1 (en) 2018-12-20
KR101890959B1 (ko) 2018-08-22
RU2591188C2 (ru) 2016-07-10
US20180022776A1 (en) 2018-01-25
HK1188730A1 (zh) 2014-05-16
SI3400944T1 (sl) 2020-11-30
PL3023102T3 (pl) 2018-11-30
US9688720B2 (en) 2017-06-27
US10981952B2 (en) 2021-04-20
AU2011326871B2 (en) 2015-02-12
US20130225511A1 (en) 2013-08-29
LTC3400944I2 (da) 2023-12-11
EP3023102A1 (en) 2016-05-25
EP3400944B1 (en) 2020-07-15
MX366925B (es) 2019-07-31
JP5889321B2 (ja) 2016-03-22
EP3777864A1 (en) 2021-02-17
CY1118125T1 (el) 2017-06-28
US10011633B2 (en) 2018-07-03
SI2637668T1 (sl) 2016-11-30
SI3023102T1 (sl) 2018-11-30
US10487111B2 (en) 2019-11-26
SG190029A1 (en) 2013-06-28
US11732006B2 (en) 2023-08-22
US20170182059A1 (en) 2017-06-29
LUC00242I2 (da) 2025-02-03
PT3023102T (pt) 2018-10-18
CY1121065T1 (el) 2020-05-29
CY2021031I1 (el) 2022-03-24
LT3023102T (lt) 2018-09-25
US11261212B2 (en) 2022-03-01
US20250326789A1 (en) 2025-10-23
DK3400944T3 (da) 2020-10-12
MX386489B (es) 2025-03-19
CN105288580B (zh) 2019-10-15

Similar Documents

Publication Publication Date Title
US12187812B2 (en) IBAT inhibitors for the treatment of liver diseases
HK40049149A (en) Ibat inhibitors for the treatment of liver diseases
HK1263167B (en) Ibat inhibitors for the treatment of liver diseases
HK1263167A1 (en) Ibat inhibitors for the treatment of liver diseases
HK1188730B (en) Ibat inhibitors for the treatment of liver diseases
HK1223566B (en) Ibat inhibitors for the treatment of liver diseases